Can you prescribe the discharge summary of Bronchial asthama
Reading File
A discharge summary is a clinical document - let me search the library for bronchial asthma management and discharge criteria, and also do a web search for standard discharge summary templates.
Finding Sources
Searching the Web
bronchial asthma discharge summary template clinical
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Now I have enough clinical information to write a thorough, well-structured discharge summary. Let me compile it.
Discharge Summary - Bronchial Asthma (Acute Exacerbation)
Below is a standard clinical discharge summary template filled in for a typical bronchial asthma admission. You can adapt the patient-specific fields to your actual case.
DISCHARGE SUMMARY
Hospital Name: _______________________________
Department: Respiratory Medicine / General Medicine / Emergency Medicine
PATIENT DETAILS
| Field | Details |
|---|---|
| Patient Name | Mr./Ms. ______________ |
| Age / Sex | ___ years / M / F |
| IP Number | ___________ |
| Date of Admission | ___________ |
| Date of Discharge | ___________ |
| Total Duration of Stay | ___ days |
| Treating Physician | Dr. ______________ |
| Ward / Bed No. | ___________ |
DIAGNOSIS
Primary Diagnosis: Bronchial Asthma - Acute Exacerbation (Moderate / Severe)
Secondary Diagnosis / Comorbidities: (e.g., Allergic Rhinitis, GERD, Obesity - if applicable)
PRESENTING COMPLAINTS (on admission)
- Sudden onset breathlessness for ___ hours/days
- Wheezing
- Cough (dry / with mucoid expectoration)
- Chest tightness
- Inability to complete sentences (in severe cases)
HISTORY
- Past History: Known case of bronchial asthma since ___ years; previous admissions/ED visits - ____
- Trigger identified: Viral URTI / Allergen exposure / Exercise / Cold air / Stress / Unknown
- Smoking history: Never / Ex-smoker / Current smoker
- Drug history: Previously on ICS / SABA / LABA - compliance: good / poor
- Family history: Asthma / Atopy / Allergic rhinitis in ___
EXAMINATION ON ADMISSION
| Parameter | Value |
|---|---|
| General Condition | Dyspneic, anxious / distressed |
| BP | ___ / ___ mmHg |
| Pulse | ___ bpm (tachycardia) |
| Respiratory Rate | ___ breaths/min (tachypneic) |
| Temperature | Afebrile / Febrile |
| SpO2 | ___% on room air |
| Peak Expiratory Flow Rate (PEFR) | ___ L/min (___% predicted) |
| Auscultation | Bilateral wheeze, prolonged expiration, reduced air entry |
Severity on admission:
- Moderate exacerbation: SpO2 92-95%, PEFR 40-69% predicted, speaks in phrases
- Severe exacerbation: SpO2 <92%, PEFR <40% predicted, speaks in words/silent chest
INVESTIGATIONS
| Investigation | Result |
|---|---|
| ABG (if done) | pH ___, pCO2 ___, pO2 ___, HCO3 ___ |
| CBC | WBC ___, Hb ___, Eosinophils ___ |
| Chest X-Ray | Hyperinflation / no consolidation / normal |
| Serum IgE (if done) | ___ IU/mL |
| Sputum (if done) | Mucoid / Curschmann's spirals / eosinophils |
| Spirometry (baseline) | FEV1/FVC ___% (obstruction pattern) |
| ECG | Sinus tachycardia / normal |
| PEFR (on day 1 / discharge) | ___ / ___ L/min |
TREATMENT GIVEN DURING ADMISSION
1. Oxygen Therapy
- Supplemental O2 via face mask / nasal prongs to maintain SpO2 >95%
2. Bronchodilators
- Nebulized Salbutamol (Albuterol) 2.5 mg every 20 min x 3 doses (first hour), then every 1-4 hours
- Nebulized Ipratropium Bromide 0.5 mg every 20 min x 3 doses (first hour, especially in moderate-severe)
3. Corticosteroids
- IV Hydrocortisone 100-200 mg every 6 hours OR
- Oral/IV Prednisolone / Methylprednisolone 1 mg/kg/day
- Switched to Oral Prednisolone 40-60 mg/day as condition improved (5-7 day course)
4. Magnesium Sulfate (if severe/life-threatening)
- IV MgSO4 2 g over 20 minutes (single dose, given if inadequate response to initial therapy)
5. IV Fluids
- Maintenance IV fluids for hydration
6. Antibiotics (only if bacterial infection confirmed or strongly suspected)
- ______________ for ___ days
7. Monitoring
- Continuous SpO2 monitoring
- PEFR measured every 4-6 hours
- Respiratory rate and heart rate charting 4-hourly
- ABG repeated if SpO2 deteriorated
CLINICAL PROGRESS
| Day | PEFR (L/min / % predicted) | SpO2 | Treatment Change |
|---|---|---|---|
| Day 1 | ___ (___%) | ___% | Nebulization q20 min x 3, then q4h |
| Day 2 | ___ (___%) | ___% | Nebulization q6h, oral steroids |
| Day 3 | ___ (___%) | ___% | Stepped down to MDI, oral steroids |
| Discharge | ___ (>70%) | >95% | MDI + steroid course |
CONDITION AT DISCHARGE
- Patient comfortable, no dyspnea at rest
- Minimal/no wheeze on auscultation
- SpO2 ___% on room air
- PEFR ___ L/min (>70% of personal best or predicted)
- Tolerating oral medications well
DISCHARGE CRITERIA MET
Per standard guidelines (NAEPP/GINA), discharge is appropriate when:
- PEFR or FEV1 is >70% of predicted or personal best
- SpO2 >95% on room air
- Symptoms minimal and patient able to walk without dyspnea
- Adequate response to bronchodilator maintained for at least 1 hour
- Patient/family understands inhaler technique and action plan
DISCHARGE MEDICATIONS
| Medication | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Salbutamol MDI (Reliever) | 100 mcg/puff, 1-2 puffs | Inhaled | As needed (every 4-6 hrs PRN) | Ongoing |
| Budesonide MDI / Fluticasone MDI (Controller - ICS) | 200-400 mcg/day | Inhaled | Twice daily | Long-term |
| Prednisolone (oral taper) | 40 mg | Oral | Once daily in morning | 5-7 days (remainder of course) |
| Montelukast (if applicable) | 10 mg | Oral | Once daily at night | Per physician |
| LABA (Formoterol / Salmeterol) - if step 3+ | Per combination inhaler | Inhaled | Twice daily | Per physician |
ADVICE AT DISCHARGE
1. Medications
- Continue all prescribed inhalers regularly - do NOT stop controller (ICS) when feeling better
- Use reliever (Salbutamol) only when needed; if using more than 2 days/week, contact your doctor
2. Inhaler Technique
- Proper MDI technique demonstrated and confirmed (shake, exhale, inhale slowly, hold 10 seconds)
- Spacer device provided/recommended (especially for children)
3. Trigger Avoidance
- Avoid known triggers: dust, smoke, pollens, pets, cold air, strong odors, viral infections
- Stop smoking (if applicable); avoid passive smoking
4. Peak Flow Monitoring (if available)
- Measure PEFR morning and evening, record in diary
- Green zone: >80% personal best - continue usual treatment
- Yellow zone: 50-80% - increase reliever, start oral steroids, call doctor
- Red zone: <50% - take reliever immediately, seek emergency care
5. Written Asthma Action Plan provided: Yes / No
6. Diet and Lifestyle
- Maintain healthy weight
- Regular exercise is encouraged (pre-treat with SABA before exercise if required)
- Adequate hydration
7. Warning signs - Return to Emergency immediately if:
- Rapid worsening of breathing not relieved by reliever inhaler
- PEFR <50% of personal best
- SpO2 <90%, blue lips or fingernails (cyanosis)
- Unable to speak in complete sentences
- Inability to walk due to breathlessness
FOLLOW-UP
- GP / Primary Care Physician: Within 1 week of discharge
- Respiratory/Pulmonology Specialist: Within 4-6 weeks (or sooner if symptoms worsen)
- Bring: Medications, peak flow diary, this discharge summary
PROGNOSIS
- Good with regular controller therapy, trigger avoidance, and adherence to action plan
- Risk of recurrence if triggers not managed or controller therapy discontinued
- Referral to allergy/immunology if allergic triggers identified
PHYSICIAN SIGNATURE
Signature: __________________
Name: Dr. __________________
Designation: __________________
Date: __________________
Sources used: Tintinalli's Emergency Medicine (9th ed.), NHLBI Asthma Care Quick Reference (NAEPP EPR-3 guidelines), and GINA discharge criteria.
Note: This is a clinical template for educational and documentation purposes. All patient-specific fields (marked with blanks) must be filled in by the treating physician with the actual patient data. Medication doses should be verified against current formulary and individualized to the patient's age, weight, and comorbidities.
Operative summary
Bronchial asthma is a medical (non-surgical) condition - it does not have a standard operative summary. However, the user may mean an operative/procedure note for an interventional procedure related to asthma, such as bronchial thermoplasty.
Let me clarify before proceeding.
Asking for Preferences
What type of operative summary are you looking for in the context of bronchial asthma?
Finding Sources
Searching the Web
bronchial thermoplasty operative procedure note summary template
Reading File
Reading File
Excellent - I now have comprehensive clinical detail. Let me compile the full operative/procedure summary.
Operative Summary - Bronchial Thermoplasty (BT) for Severe Bronchial Asthma
OPERATIVE / PROCEDURE SUMMARY
PATIENT DETAILS
| Field | Details |
|---|---|
| Patient Name | ___________________ |
| Age / Sex | ___ years / M / F |
| IP / OP Number | ___________ |
| Date of Procedure | ___________ (Session 1 / 2 / 3) |
| Location | Bronchoscopy Suite / Endoscopy Unit |
| Surgeon / Bronchoscopist | Dr. ______________ |
| Assisting Physician | Dr. ______________ |
| Anesthesiologist | Dr. ______________ |
| Scrub Nurse / Technician | ______________ |
PRE-PROCEDURE DIAGNOSIS
Severe Persistent Bronchial Asthma - uncontrolled despite maximal inhaled therapy (ICS + LABA)
PROCEDURE PERFORMED
Bronchial Thermoplasty (BT) - Session ___ of 3
(Session schedule: Session 1 - Right lower lobe | Session 2 - Left lower lobe | Session 3 - Both upper lobes; right middle lobe excluded per standard protocol)
INDICATION
- Adult patient with severe persistent asthma
- Poorly controlled on maximally tolerated inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) therapy
- Candidate selected after exclusion of comorbid contributors (GERD, rhinosinusitis, vocal cord dysfunction)
- No implantable electronic device (pacemaker / ICD)
- No severe comorbid conditions precluding bronchoscopy
- Patient counselled and informed consent obtained
CONTRAINDICATIONS EXCLUDED
- Implantable cardiac electronic device: Absent
- Active respiratory infection: Excluded
- Severe coagulopathy: Excluded
- Allergy to sedative agents: Excluded
- Age < 18 years: Not applicable
PRE-PROCEDURE PREPARATION
- Pre-procedure pulmonary function tests (PFTs) / spirometry reviewed: FEV1 ___% predicted
- Pre-procedure chest X-ray / HRCT reviewed
- Baseline PEFR: ___ L/min
- Bronchodilator pre-treatment: Salbutamol nebulization given 1 hour prior
- Oral Prednisolone 50 mg given for 3 days prior to procedure (to minimize post-procedure inflammation)
- NPO (nil by mouth) from ___ hours prior
- IV access secured; monitoring attached (ECG, SpO2, NIBP)
- Informed consent documented
ANESTHESIA / SEDATION
- Type: Conscious sedation (no general anesthesia required)
- Agent(s): IV Midazolam ___ mg + IV Fentanyl ___ mcg
- Topical airway anesthesia: Lignocaine (lidocaine) spray / nebulization to oropharynx and airways
- Supplemental O2: Via nasal cannula at ___ L/min throughout procedure
- SpO2 maintained: >95% throughout
EQUIPMENT
- Flexible bronchoscope (Olympus / Pentax - model: ______)
- Alair Bronchial Thermoplasty System (Boston Scientific):
- Radiofrequency (RF) generator
- Disposable catheter with expandable four-electrode basket at distal tip
- Working channel diameter compatible with catheter passage
OPERATIVE PROCEDURE - STEP BY STEP
1. Positioning and Access
- Patient positioned supine on bronchoscopy table
- Supplemental oxygen applied; monitors attached
- Topical anesthesia applied to oropharynx
- Flexible bronchoscope introduced via the oral / nasal route under conscious sedation
2. Airway Inspection
- Systematic bronchoscopic survey performed
- Mucosa assessed for edema, erythema, secretions
- Secretions cleared by gentle suction
- Airway anatomy confirmed
- Target lobe confirmed: Right Lower Lobe / Left Lower Lobe / Both Upper Lobes
3. Catheter Deployment
- Thermoplasty catheter introduced through the working channel of the bronchoscope
- Catheter advanced to the distal subsegmental airways under direct vision
- Four-electrode basket expanded to make contact with the airway wall
- Proper contact with airway wall confirmed before energy delivery
4. Radiofrequency Energy Delivery
- Controlled RF energy delivered at each site:
- Temperature: 65°C per activation
- Duration: 10 seconds per activation
- Activations performed in a systematic fashion at 5-mm intervals
- Delivery started from just beyond the endoscopic visual limit, progressing sequentially to the proximal lobar bronchi (distal-to-proximal technique)
- Total number of activations this session: ___
- Each activation separated by adequate interval to allow tissue cooling
5. Progression Through Targeted Segments
(Session-specific bronchopulmonary segments treated - mark all that apply)
| Segment | Treated (Yes/No) | No. of Activations |
|---|---|---|
| Right B7 (medial basal) | ||
| Right B8 (anterior basal) | ||
| Right B9 (lateral basal) | ||
| Right B10 (posterior basal) | ||
| (Or Left / Upper lobe segments per session) | ||
| Total activations |
6. Post-Treatment Airway Assessment
- Airways inspected after energy delivery
- Mucosal response noted: mild erythema / edema (expected)
- No endobronchial bleeding, mucosal sloughing, or perforation
- Bronchoscope withdrawn under direct vision
INTRAOPERATIVE FINDINGS
- Airway mucosa: Mild erythema / hyperemia (expected inflammatory response)
- Secretions: Minimal / moderate mucoid
- No bleeding, no bronchospasm, no pneumothorax
- Patient tolerated procedure well / with mild coughing (managed with additional topical lignocaine)
- SpO2 remained stable throughout at ___% on supplemental O2
- Total procedure duration: ___ minutes
COMPLICATIONS
- Intraoperative complications: None / Mild bronchospasm (managed conservatively)
- Any emergency intervention required: No
- Post-procedure respiratory status: Stable
POST-PROCEDURE CARE
- Patient monitored in recovery for minimum 2 hours
- Post-procedure nebulized salbutamol administered
- SpO2 monitoring continued until patient awake, alert, and SpO2 stable on room air
- Chest X-ray post-procedure: ___ (to exclude pneumothorax)
- Oral Prednisolone continued for ___ days post-procedure
- Resume normal oral intake once fully awake
DISCHARGE / NEXT STEPS
- Patient discharged on the same day (outpatient) / admitted for overnight observation
- Next BT session scheduled in 2-3 weeks: _________ (date)
- Instructions given:
- Return immediately if: worsening dyspnea, high fever, chest pain, SpO2 drop
- Continue all regular asthma medications as prescribed
- Avoid strenuous activity for 24-48 hours post-procedure
SESSION SCHEDULE SUMMARY
| Session | Target Lobe | Planned Date | Status |
|---|---|---|---|
| Session 1 | Right Lower Lobe | ______ | Done / Pending |
| Session 2 | Left Lower Lobe | ______ | Done / Pending |
| Session 3 | Both Upper Lobes | ______ | Done / Pending |
(Right middle lobe is NOT treated - excluded per original trial protocol)
EXPECTED OUTCOMES (to counsel patient)
- Per the AIR2 trial (FDA-approval pivotal study): 30% reduction in severe asthma exacerbations, 80% reduction in ED visits, and fewer days missed from work/school
- Benefits shown to be durable at 5-year follow-up
- A transient increase in asthma-related symptoms and possible increased hospitalizations may occur in the perioperative period - this is expected and self-limiting
- Full benefit typically realized 6-12 months after completing all 3 sessions
OPERATOR SIGNATURE
Bronchoscopist Signature: _______________
Name: Dr. _______________
Designation: Consultant Pulmonologist / Interventional Pulmonologist
Date: _______________
Sources: Murray & Nadel's Textbook of Respiratory Medicine, Fishman's Pulmonary Diseases and Disorders, AIR2 Trial (FDA-approval basis), Boston Scientific Alair BT System protocol.
Note: All patient-specific fields (blanks) must be filled in by the treating physician. This template follows the standard 3-session BT protocol with the Alair System. Dosing and technique should be confirmed against the current device IFU (Instructions for Use) and institutional protocol.
This is a shared conversation. Sign in to Orris to start your own chat.